MOLECULAR AND GENETIC ALTERATIONS IN ICC

Common Genetic Mutations in Intrahepatic Cholangiocarcinoma (e.g., IDH1/2, FGFR2, BAP1, TP53)

Intrahepatic cholangiocarcinoma, a malignancy originating from the bile ducts in the liver, displays specific genetic alterations that influence its development, progression, and treatment response [27]. Progress in genomic profiling has shown multiple recurring mutations in intrahepatic cholangiocarcinoma (iCCA), with IDH1/2, FGFR2, BAP1, and TP53 being the most prevalent (Fig. 2) [109]. IDH1/2 mutations are present in around 15-20% of intrahepatic cholangiocarcinoma patients [28]. These mutations lead to the synthesis of an oncometabolite, 2-hydroxyglutarate, which interferes with normal cellular metabolism and epigenetic control, hence facilitating cancer. Targeted inhibitors of mutant IDH enzymes, including ivosidenib, have demonstrated potential in the treatment of IDH-mutant iCCA. FGFR2 fusions and rearrangements occur in approximately 10-15% of iCCA patients [29]. These modifications result in the constitutive activation of the FGFR2 signaling pathway, promoting unregulated cell proliferation and survival. FGFR inhibitors, such as pemigatinib, have received approval for FGFR2 fusion-positive iCCA, highlighting the significance of molecular testing for tailored treatment. Mutations in BAP1, a tumor suppressor gene implicated in chromatin remodeling and DNA repair, are present in a subset of iCCA patients. The loss of BAP1 function correlates with genomic instability and heightened vulnerability to malignant transformation [30]. TP53, a gene commonly altered in numerous malignancies, is essential for the regulation of the cell cycle and apoptosis. TP53 mutations are associated with more aggressive tumor characteristics and a worse prognosis in iCCA patients [31]. Comprehending these genetic modifications has profoundly impacted the formulation of individualized therapeutic approaches. Molecular analysis of iCCA tumors facilitates the identification of actionable mutations, permitting tailored medicines that enhance patient outcomes and provide new optimism in the management of this complex malignancy.

Chromosomal Abnormalities and Gene Amplifications

Chromosomal abnormalities and gene amplifications significantly contribute to the development and progression of intrahepatic cholangiocarcinoma (iCCA). These genetic modifications interfere with normal cellular functions, facilitating tumor proliferation, persistence, and metastasis. Frequent chromosomal anomalies in iCCA encompass both amplifications and deletions of particular chromosomal regions [32]. Chromosomal gains are frequently detected at 1q, 7p, 8q, and 17q locus genes. These areas frequently include oncogenes whose overexpression can induce cancer. In contrast, chromosomal losses frequently occur on 3p, 6q, 9p, and 14q, resulting in the deletion or inactivation of tumor suppressor genes, which facilitates malignant transformation and progression. Gene amplifications augment oncogenic signaling pathways in iCCA. Prominent amplified genes encompass ERBB2 (HER2), MET, and MDM2. Amplification of ERBB2 (HER2) results in excessive activation of the HER2 signaling pathway, facilitating cellular proliferation and survival. Likewise, MET amplification augments the hepatocyte growth factor (HGF) pathway, facilitating tumor proliferation and metastasis. HER2 and MET amplifications represent viable therapeutic targets, with HER2-targeted medicines and MET inhibitors demonstrating potential in clinical studies [33]. MDM2 amplification impedes the tumor suppressor function of p53, leading to less apoptosis and enhanced cell proliferation. Furthermore, CCND1 amplification results in cyclin D1 overexpression, which impairs cell cycle regulation and fosters unregulated cellular proliferation [34]. These genetic modifications enhance our comprehension of iCCA pathophysiology and underscore potential biomarkers for targeted therapeutics, facilitating more individualized treatment strategies in iCCA management.

Somatic vs. Germline Mutations in ICC

In iCCA, somatic and germline mutations contribute to disease development and progression, although with distinct origins and implications [35, 36]. Somatic mutations arise in non-germline cells and are acquired during an individual's life, frequently as a result of environmental influences, persistent inflammation, or random errors in DNA replication. These mutations are not inherited nor transmitted to progeny [37]. Frequent somatic mutations in iCCA encompass modifications in IDH1/2, FGFR2 fusions, BAP1, and TP53, all of which are susceptible to targeted precision therapy. Conversely, germline mutations are hereditary genetic modifications found in all bodily cells, including gametes, and can be transmitted to subsequent generations. Germline mutations linked to iCCA are infrequent but may affect tumor suppressor genes, like BRCA1/2 or MLH1, associating iCCA with hereditary cancer disorders. Identifying germline mutations is crucial for familial risk evaluation, whereas somatic mutations guide customized therapeutic approaches.

Role of Epigenetic Modifications in Cholangiocarcinoma Progression

Epigenetic changes are essential in the advancement of CCA by modulating gene expression without changing the DNA sequence. Principal epigenetic mechanisms encompass DNA methylation, histone changes, and non-coding RNAs. Aberrant DNA methylation frequently results in the silencing of tumor suppressor genes, including p16INK4a and RASSF1A, hence facilitating unchecked cellular proliferation and evasion of apoptosis. Histone changes, such as acetylation and methylation, modify chromatin architecture, influencing the transcription of genes pertinent to cell cycle regulation and metastasis. The overexpression of histone-modifying enzymes, such as EZH2, is associated with unfavorable outcomes in CCA. Furthermore, non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), modulate gene expression via governing mRNA stability and translation. The dysregulation of particular miRNAs, such as miR-21, facilitates tumor proliferation, invasion, and resistance to chemotherapy. The reversible nature of these epigenetic alterations presents opportunities for tailored therapeutics employing epigenetic inhibitors to impede CCA progression and enhance patient outcomes. Repetitive and satellite DNA elements are essential for genomic integrity, and their dysregulation is frequently observed in numerous malignancies. These components, such as long interspersed nuclear elements (LINEs) and satellite DNA, frequently encounter hypomethylation, resulting in genomic instability, modified gene expression, and heightened tumor aggressiveness [38]. In CCA, research indicates that CpG island hypermethylation occurs early in tumor development, but repetitive DNA hypomethylation is noted in later stages. Methylation levels of LINE-1 and satellite 2 (SAT2) are markedly reduced in CCA relative to normal bile duct tissues, signifying a lack of epigenetic regulation. This hypomethylation may lead to chromosomal instability and tumor progression. Comparable patterns of repeated element dysregulation have been identified in other malignancies, including prostate cancer, where hypermethylation of satellite DNA has been associated with tumor growth [39]. Moreover, microsatellite instability (MSI), a condition linked to mismatch repair deficiency, has been related to multiple cancers, including colorectal and gastric malignancies. The findings indicate that epigenetic modifications in repeated sequences may function as potential biomarkers for cancer diagnosis and prognosis.

Genomic and Transcriptomic Insights into Cholangiocarcinoma: A Comparative Analysis with Osteosarcoma

CCA is a very diverse and aggressive neoplasm with restricted treatment alternatives. Recent genomic and transcriptomic investigations have yielded significant insights into its molecular architecture. A study performed a multi-omics characterization of CCA, incorporating whole-genome sequencing (WGS), whole-exome sequencing (WES), RNA sequencing, and whole-genome bisulfite sequencing (WGBS) to categorize CCA into four unique molecular subtypes. These subgroups demonstrated distinct tumor microenvironment attributes and varying responses to immune checkpoint blockade therapy [40]. A separate study investigated the clonal evolution of CCA by whole-exome and transcriptome sequencing, demonstrating the impact of genomic mutations on transcriptomic changes and tumor progression. This work emphasized the relationship between somatic mutations and gene expression, offering insights into tumor heterogeneity. In comparing CCA with osteosarcoma, both cancers display intricate genomic landscapes; nevertheless, osteosarcoma is distinguished by significant chromosomal rearrangements and a pronounced mutation burden [41]. CCA research concentrates on interactions within the immunological microenvironment and epigenetic modifications, whereas osteosarcoma studies frequently highlight genomic instability and abnormalities in tumor suppressor genes. A transcriptome investigation found oxidative stress-related molecular subgroups in CCA, which may function as prognostic indicators. This research work employed data from The Cancer Genome Atlas (TCGA) to construct a predictive model centered on oxidative stress-related genes. The findings indicated that multi-omics methodologies are essential for comprehending CCA and formulating targeted treatments.